A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of RGT001-075 Compared With Placebo in Adult Patients With Obesity or Overweight
Latest Information Update: 22 Jan 2025
Price :
$35 *
At a glance
- Drugs RGT 075 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Regor Therapeutics
- 10 Jan 2025 Status changed from active, no longer recruiting to completed, According to Regor Therapeutics media release.
- 10 Jan 2025 Topline results presented in the Regor Therapeutics Media Release.
- 28 May 2024 Status changed from recruiting to active, no longer recruiting.